UK Website

ONTOZRY® is taken orally, ONCE DAILY1

  • ONTOZRY® can be taken at any time of the day, preferably at the same time each day
  • The recommended starting dose is 12.5 mg/day
  • Titrate up gradually, every two weeks, to reach the recommended target dose of 200 mg/day
  • Dose may be increased gradually to a maximum of 400 mg/day based on your patient’s clinical response

Recommended ONTOZRY® titration schedule in adults with focal onset seizures in epilepsy, which should not be exceeded because of the potential for serious adverse reactions1

Dose optimisation

Some patients, who do not reach optimal seizure control, may benefit from doses above 200 mg (increased by increments of 50 mg/day every two weeks) up to a maximum of 400 mg daily.1

Missed dose

If patients miss one dose, it is recommended that they take a single dose as soon as they remember, unless it is less than 12 hours until their next regularly scheduled dose.1

Discontinuation

It is recommended that discontinuation be undertaken gradually to minimise the potential for rebound seizures (i.e. over at least 2 weeks), unless safety concerns require abrupt withdrawal.1

ONTOZRY® is not indicated for children aged 0 months to 18 years.1
ONTOZRY® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients (see the Summary of product characteristics for the full list).1
ONTOZRY® is contraindicated in patients with Familial Short QT syndrome.1
ONTOZRY® is not recommended in women of childbearing potential not using contraception. Women of reproductive potential concomitantly using oral contraceptives should practice additional or alternative non-hormonal measures of birth control during treatment with ONTOZRY® and until 4 weeks after treatment discontinuation.1
For considerations in other selected patient populations (elderly patients, hepatic impairment, renal impairment), see the Summary of product characteristics for full prescribing information.1

Reference:

1. ONTOZRY® Summary of product characteristics.

P-UK-CE-2100020 | December 2021

Feedback